The FDA issued warning letters to two companies for illegally selling unapproved products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act. The agency stated it is part of its efforts to pursue companies that illegally market CBD products claiming to treat medical conditions, including opioid addiction or as an alternative to opioids.
APRIL 24, 2020